Project Grant R01CA308972
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $639K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14263, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded $138,846 to the University Health Network under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for a two-year Project Grant commencing August 1, 2025 and concluding July 31, 2027. The award supports the development of laboratory-generated "wild-like" mouse models designed to enhance the translational relevance of preclinical cancer and immunotherapy research. The primary deliverable involves adapting...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Institute For Cancer Research a Project Grant of $766,439 under the Cancer Cause and Prevention Research program (CFDA 93.393) for the period April 1, 2026 through March 31, 2031. This research project focuses on intratumor heterogeneity as a correlate of clinical outcomes in bladder cancer patients pursuing cystectomy avoidance strategies. The primary deliverables include: (1) scientific investigation into the genetic...
- Federal Grant Award Summary Health Research, Inc. (operating as Health Research at Roswell Park) received a $173,500 Project Grant awarded August 7, 2025, by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to conduct a correlative clinical study investigating the effects of CXCR1/2 inhibition on the immune microenvironment of multiple myeloma patients. The research leverages preliminary findings demonstrating significant accumulation of CXCR2-positive...
- Federal Grant Award Summary The National Cancer Institute awarded a $730,398 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) beginning April 1, 2026, and extending through March 31, 2031. This award supports research investigating tumor regenerative cell (TRC) populations that drive resistance to neoadjuvant therapy and metastatic recurrence in locally advanced rectal cancer (LARC). The research deliverables include genomic...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $483,395 project grant under the Cancer Treatment Research program (CFDA 93.395) beginning September 1, 2025 and concluding August 31, 2027. This grant funds research investigating P300/CBP (lysine acetyltransferases) as novel therapeutic targets in clear cell renal cell carcinoma (ccRCC). The research will examine the therapeutic potential of targeting P300/CBP through pharmacological...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2028. The award supports research to decipher mechanisms of resistance to anti-TROP2 (tumor-associated glycoprotein 2) antibody-drug conjugates, specifically sacituzumab govitecan (SG), which is currently approved for treating advanced...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a Project Grant of $658,492 under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate a novel targeted combinatorial therapy for advanced castration-resistant prostate cancer (ACRPC). The research, spanning from March 18, 2026 through February 28, 2031, focuses on optimizing the combination of CHK1 inhibitor SRA737 and WEE1 inhibitor AZD1775 to exploit the G2/M...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $168,000 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective July 1, 2025, with completion scheduled for June 30, 2027. The award funds research to examine risk factors and develop predictive models for multiple recurrences of non-muscle invasive bladder cancer (NMIBC). The research leverages existing demographic, lifestyle,...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...